STANFORD, Calif.--(BUSINESS WIRE)--The Stanford University School of Medicine is recruiting participants for a clinical trial to determine the safety of an experimental vaccine against the new H1N1 strain of influenza when the vaccine is combined with an immune-stimulating substance called an adjuvant. The trial will also examine whether use of the adjuvant improves the immune response to the vaccine.
